An Alzheimer’s re­jec­tion; Our #JPM23 dis­patch­es; Count Mod­er­na in for RSV; Biotech lay­offs per­sist; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We be­gan the week with an Amer­i­can hol­i­day and now end with an East Asian one. Hap­py Lu­nar New Year to all who cel­e­brate!

An Alzheimer’s re­jec­tion

Just days af­ter wav­ing through Bio­gen and Ei­sai’s Leqem­bi, the FDA squashed ac­cel­er­at­ed hopes for Eli Lil­ly’s Alzheimer’s drug, ask­ing for more da­ta. Lil­ly said reg­u­la­tors de­nied the ac­cel­er­at­ed ap­proval for its an­ti-amy­loid an­ti­body, do­nanemab, “based on lim­it­ed num­ber of pa­tients with 12-month drug ex­po­sure da­ta” in the sub­mis­sion. The com­pa­ny had been plan­ning to file for full ap­proval once it re­ports Phase III da­ta lat­er this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.